 MALVERN, Penn., Dec. 02, 2022 GLOBE NEWSWIRE Baudax Bio, Inc. the Company or Baudax Bio NASDAQ: BXRX, a pharmaceutical company focused on therapeutics for acute care settings, today announced the pricing of a public offering of an aggregate of 1,042,787 shares of its common stock or pre-funded warrants in lieu thereof, Series A-3 warrants ... The post Baudax Bio Announces Pricing of 5 Million Public Offering appeared first on ForexTV... 